Celsion CEO Michael Tardugno - An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Tardugno speaks with the DAILY about the regulatory timeline and commercialization plans for ThermoDox, including plans to market the heat-activated liposomal-delivery doxorubicin in Asia.
You may also be interested in...
Celsion CEO Michael Tardugno – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Tardugno speaks with the DAILY about his company’s transition from a device firm to an oncologic development company and about its proprietary technology.
Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.